MSK SPORE in Lymphoma External Advisory Board Meeting July 15, 2019 Room: ZRC 105 10:30am-6:00pm Agenda			
10:30-10:35am	Welcome Remarks and Introduction to the MSK Lymphoma SPORE	Anas Younes and Andrew Zelenetz, Co-Directors of the MSK Lymphoma SPORE	
10:35-10:45 am	Administrative Core	Anas Younes	
10:45-11:05 am	Project 1: "Development of Mechanism-Based Therapy for Myc+/Bcl2+ Diffuse Large B Cell Lymphoma" Proposed New Project: "Dual inhibition of mcl-1 and bcl-2 in lymphoma using targeted nanoparticles for drug delivery"	Anas Younes	
11:05-11:15 am	Discussion		
11:15-11:35am	Proposed New Project: "Contribution of oncogenic translation programs to lymphoma biology and therapy"	Guido Wendel	
11:35-11:45am	Discussion		
11:45-12:05pm	Project 2: "Autologous CD19 targeted 19-28z+ T cells for the treatment of relapsed diffuse large B cell lymphoma in transplant ineligible elderly patients"	Brentjens, Batlevi	
12:05-12:15pm	Discussion		
12:15-12:35pm	Project 3: "Translating Stress Response Targeted Therapy for B-Cell Lymphomas"	Melnick, Chiosis, Leonard	
12:35- 12:45pm	Discussion		
12:45 -1:05pm	Project 4: "Targeting Acetyltransferase Gene Inactivation in Diffuse Large B Cell Lymphoma"	Pasqualucci, Zelenetz, Dalla- Favera	
1:05-1:15pm	Discussion		
1:15-2:15pm	Lunch Break		
2:15-3:15pm	Proposed New Projects (CEP and DRP)		
2:15-2:35pm	Proposed New Project emerged from DRP: "Development of Malt1 inhibition regimens for B- cell lymphomas"	Lorena Fontan, Ari Melnick	

2:35-2:45pm	Discussion	
2:45-3:05pm	Proposed New Project emerged from CEP: "Targeting the Nicotinamide Adenine Dinucleotide salvage pathway in Diffuse Large B Cell Lymphoma"	Claudio Scuoppo, Riccardo Dalla-Favera
3:05-3:15pm	Discussion	
3:15-3:45 pm	Break	
	Career Enhancement Program	
3:45-4:00pm	CEP Program Overview	Andrew Zelenetz
4:00-5:00pm	Developmental Research Program	
	DRP Program Overview (15min)	John Leonard
	David Dominguez-Sola: "Functional bypass of cell cycle entry checkpoints by MYC mutations in aggressive B-cell lymphomas" (15 min)	
	Lorena Fontan: "Role of BCL10 somatic mutations in lymphomagenesis and response to BCR- targeted therapies" (15 mins)	
5:00-5:30pm	<u>Cores</u> Biostatistics and Bioinformatics (15min) Biospecimen (15min)	V. Seshan A. Dogan
5:30-6:00pm	Closing Remarks and Future Plans	Anas Younes, Andrew Zelenetz